SNPMiner Trials (Home Page)
Report for SNP rs12459419
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 A Phase 2 Trial of Fractionated Gemtuzumab Ozogamicin to Eradicate Measurable Residual Disease in Acute Myeloid Leukemia Patients (GO for MRD)
This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in participants with acute myeloid leukemia. Immunotherapy with monoclonal antibodies, such as gemtuzumab ozogamicin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
NCT03737955 Acute Myeloid Leukemia CD33 Positive Minimal Residual Disease Drug: Gemtuzumab Ozogamicin Other: Quality-of-Life Assessment MeSH:Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasm, Residual
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Leukemia Myeloid leukemia
Measured by clearance of measurable residual disease (MRD) with bone marrow evaluation after one or two cycles of therapy and compare responses (rate of eradication of MRD) based on CD33 single nucleotide polymorphism rs12459419 genotype.. Rate of sinusoidal obstructive syndrome (SOS).
Primary Outcomes
Description: Measured by clearance of measurable residual disease (MRD) with bone marrow evaluation after one or two cycles of therapy and compare responses (rate of eradication of MRD) based on CD33 single nucleotide polymorphism rs12459419 genotype.
Measure: Clinical response rate Time: Up to 70 daysSecondary Outcomes
Description: Measured by grade III/IV non-hematologic toxicities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.
Measure: Rate of sinusoidal obstructive syndrome (SOS) Time: Up to 6 monthsDescription: Measured by those receiving HCT
Measure: Rate of allogeneic hematopoietic cell transplantation (HCT) Time: Up to 6 Months